Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03552133
Other study ID # 2016-0475
Secondary ID A538500SMPH/POP
Status Completed
Phase N/A
First received
Last updated
Start date August 2016
Est. completion date October 1, 2019

Study information

Verified date October 2019
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to determine the feasibility of using a novel treatment for sleep apnea in which the patient's own exhaled CO2 is tightly controlled and used in a rebreathe system to reduce sleep disordered breathing.


Description:

Obstructive sleep apnea (OSA) needs to be treated with devices that will be utilized with greater compliance by patients than is currently the case with positive airway pressure. To this end, the investigators recently showed that increased inspired CO2 via rebreathing was effective in reducing most obstructive and central apneas in OSA patients. Then, the investigator's University of Wisconsin (UW) team of bioengineers, physiologists, and sleep physicians built a novel variable dead space rebreathe device—with no added positive pressure—which monitors breath by breath ventilation and automatically adjusts the rebreathe dead space volume to add or subtract the level of inspired CO2 depending on the degree of sleep disordered breathing. This approach provides the minimum effective CO2 dose needed in individual OSA patients to stabilize central respiratory motor output and to recruit upper airway dilator muscles, thereby treating obstructive and central apneas. The investigators propose to determine the effectiveness of this "Smart CO2" treatment as well as its effects on sleep state stability, sleep quality, and blood pressure in 10 moderate to severe OSA patients studied over several nights. The investigators expect the findings from the proposed study to be sufficient to determine if the "Smart CO2" treatment is a viable approach to OSA treatment worthy of testing in a clinical trial.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date October 1, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age 18-75 years old, inclusive

2. Moderate to severe OSA (Apnea hypopnea index [AHI] >15 events/hr of sleep)

3. Newly diagnosed OSA, or have either refused to or have not tolerated PAP treatment, or are currently using Positive Airway Pressure (PAP) and are willing to hold it during the night of sleep study visits.

4. Willing and able to provide consent to 5 laboratory visits with 4 full nights of sleep study.

5. Self report of still having sleep apnea since the last sleep test (if diagnosis was greater than a year prior).

Exclusion Criteria:

1. BMI >45 kg/m2

2. AHI<15 events/hour on the first night of sleep testing in our research laboratory (Visit 2)

3. Cigarette smoking of 1 pack per day or more within 6 months of screening;

4. Diagnosed heart failure or coronary artery disease.

5. Diagnosed cerebrovascular disease, Transient Ischemic Attack (TIA) or stroke.

6. Diagnosed asthma or chronic obstructive pulmonary disease with significant airways obstruction (FEVI/Forced Vital Capacity <65%)

7. End-stage hepatic or renal disease

8. Significant daytime sleepiness in subjects who have risky occupations or life-style (for example, working in the transportation industry, history of motor vehicle crash, occupation that requires vigilance for safety or performance)

9. Pregnancy (assessed on urine test at V1 in females with childbearing potential)

10. Clinically significant arrhythmia/dysrhythmias on the clinical diagnostic polysomnography (per medical record) or on research polysomnography conducted at V2

11. Established diagnosis of neuromuscular disease (e.g., Parkinsonism, multiple sclerosis, syringomyelia, transverse myelitis, amyotrophic lateral sclerosis, poliomyelitis, Eaton-Lambert, Guillain-Barre, myasthenia gravis, myotonic dystrophy, mononeuritis multiplex, in the setting of polymyositis/dermatomyositis or severe cervical spine disease)

12. Any current use of benzodiazepines, opioids, or barbiturates

13. Any medical or psychiatric condition which in the opinion of the medical director interferes with the subject's ability to enroll or to continue in the study (once enrolled)

14. Veteran, cared for in the VA system

Study Design


Intervention

Device:
Smart CO2
A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.

Locations

Country Name City State
United States University of Wisconsin Madison Madison Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aim 1: Determine the effects of Smart CO2 Device on AHI To determine the effects of a novel, adjustable CO2 rebreathing device on the occurrence of sleep apnea (AHI) in patients with moderate to severe obstructive sleep apnea. three to six weeks
Primary Determine the effect of Smart C02 Device on Arousal Index To determine the effects of a novel, adjustable CO2 rebreathing device on the occurrence of sleep apnea (Arousal Index) in patients with moderate to severe obstructive sleep apnea. three to six weeks
Secondary Aim 2: Effect on Sleep state stability To determine whether this novel treatment influences sleep state stability following sleep. Three to six weeks
Secondary Determine the effects of Smart CO2 device on Blood pressure (both systolic and diastolic measures) To determine whether this novel treatment influences systolic or diastolic blood pressure following sleep. Three to six weeks
See also
  Status Clinical Trial Phase
Terminated NCT03605329 - Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS N/A
Completed NCT04912635 - Evaluation of a Health Dashboard Intervention to Improve Engagement With CPAP Therapy in PAP-Naïve Patients: Project Neo N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Enrolling by invitation NCT02290236 - Monitored Saturation Post-ICU N/A
Completed NCT02088723 - Testing the Elevation as Sleep Apnea Treatment N/A
Terminated NCT02269774 - Origin of Premature Atrial Beats Induced by Simulated Obstructive Sleep Apnea N/A
Completed NCT02261857 - 3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea Early Phase 1
Completed NCT01943708 - Novel Auto-continuous Positive Airway Pressure (CPAP) Validation Phase 3
Completed NCT01181570 - Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Phase 4
Completed NCT00273754 - The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA). Phase 2
Recruiting NCT02166879 - Undetected Sleep Apnea in the Postanesthesia Acute Care Unit (PACU)
Recruiting NCT04963192 - Integrated Management of Chronic Respiratory Diseases N/A
Completed NCT04846400 - Pilot Study of a Self-Supporting Nasopharyngeal Airway in Hypotonia N/A
Completed NCT05056766 - How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement
Recruiting NCT04314492 - Intracapsular Tonsillectomy in the Treatment of Obstructive Sleep Apnea in Adults N/A
Completed NCT05175287 - OSA (oRisk of Obstructive Sleep Apnea and Traffic Accidents Among Bus Drivers in Ecuador: is There a Significant Association
Active, not recruiting NCT03431038 - Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH N/A
Enrolling by invitation NCT03075787 - Cardiovascular Variability and Heart Rate Response Associated With Obstructive Sleep Apnea N/A
Completed NCT03300037 - HYpopnea and Apnea Detection and Treatment Performance of a New cardiOreSpiratory Holter Monitor N/A
Recruiting NCT06097949 - AcuPebble to Remotely Monitor Patients With OSA on CPAP Therapy